Cardiovascular Drugs Practice Questions

Q: A 40-year-old male patient has type II diabetes mellitus and hypertension. Which of the following antihypertensive drugs should be avoided in such patients?

Hydrochlorothiazide. ### Explanation **Correct Option: B. Hydrochlorothiazide** **Why Hydrochlorothiazide is avoided:** Thiazide diuretics like Hydrochlorothiazide are generally avoided or used with caution in patients with Diabetes Mellitus due to their **metabolic side effects**. They can cause **hyperglycemia** by inhibiting insulin release from pancreatic beta cells and decreasing peripheral glucose utilization. Additionally, thiazides can lead to hypokalemia, which further impairs insulin secretion. They also tend to increase LDL cholesterol and triglycerides, worsening the metabolic profile of a diabetic patient. **Why the other options are incorrect:** * **A, C, and D (Lisinopril, Losartan, Trandolapril):** These drugs belong to the classes of **ACE Inhibitors** (Lisinopril, Trandolapril) and **Angiotensin Receptor Blockers (ARBs)** (Losartan). In fact, these are the **drugs of choice** for hypertensive patients with diabetes. They provide **renoprotection** by dilating the efferent arteriole, reducing intraglomerular pressure, and slowing the progression of diabetic nephropathy (microalbuminuria). **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** For Hypertension with Diabetes = ACE Inhibitors or ARBs. * **Metabolic Side Effects of Thiazides:** Remember the mnemonic **"Hyper-GLUC"**: Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia. * **Beta-Blockers:** Also used with caution in diabetics as they can mask the autonomic symptoms of hypoglycemia (like tachycardia and tremors) and may delay recovery from a hypoglycemic episode. * **Calcium Channel Blockers (CCBs):** These are metabolically neutral and are considered safe second-line agents in diabetic patients.

Q: Which among the following is the best inotrope drug for use in right heart failure?

Milrinone. **Explanation:** **Milrinone** is the drug of choice for right heart failure (RHF) because of its unique dual mechanism as an **"Inodilator."** It is a selective **Phosphodiesterase-3 (PDE-3) inhibitor** that increases intracellular cAMP. 1. **Inotropy:** It increases myocardial contractility. 2. **Vasodilation:** Crucially, it causes potent **pulmonary vasodilation**, which reduces Pulmonary Vascular Resistance (PVR). In RHF, the right ventricle is highly sensitive to afterload; by lowering pulmonary pressures, Milrinone reduces the workload on the right heart while simultaneously improving its pumping capacity [3]. **Why other options are incorrect:** * **Dobutamine:** While a potent $\beta_1$ agonist (inotrope), it is less effective than Milrinone at reducing pulmonary artery pressure [1]. It also increases myocardial oxygen demand more significantly, which can be detrimental in ischemic states. * **Digoxin:** It has weak inotropic effects and is primarily used for rate control in atrial fibrillation [2]. It does not provide the acute afterload reduction required in RHF [4]. * **Dopamine:** At higher doses, it causes alpha-1 mediated vasoconstriction, which can increase pulmonary artery pressure (increasing right ventricular afterload), making it less ideal for RHF [1]. **Clinical Pearls for NEET-PG:** * **Milrinone Side Effect:** The most common side effect is **arrhythmia** and **hypotension** (due to systemic vasodilation). * **Renal Clearance:** Milrinone is renally excreted; dosage adjustment is required in patients with renal impairment. * **Inodilators:** This term refers to drugs like Milrinone and Levosimendan that combine positive inotropy with systemic and pulmonary vasodilation [3].

Q: Which of the following drugs can prolong survival in patients with Congestive Heart Failure (CHF)?

Losartan. **Explanation:** In Congestive Heart Failure (CHF), the primary goal of therapy is to counteract the maladaptive neurohormonal activation (specifically the Renin-Angiotensin-Aldosterone System and the Sympathetic Nervous System) that leads to cardiac remodeling and fibrosis. **Why Losartan is Correct:** Losartan is an **Angiotensin II Receptor Blocker (ARB)**. Like ACE inhibitors, ARBs prevent the deleterious effects of Angiotensin II on the myocardium. By blocking AT1 receptors, they inhibit cardiac remodeling, reduce afterload, and decrease mortality. Drugs that modify the disease process (ACEIs, ARBs, Beta-blockers, Spironolactone, and SGLT2 inhibitors) are proven to **prolong survival** in CHF. **Why the others are Incorrect:** * **Furosemide (Option A):** A loop diuretic used for symptomatic relief of pulmonary and peripheral edema. While essential for managing "wet" heart failure, it does not decrease mortality. * **Inamrinone (Option B):** A PDE-3 inhibitor (Inodilator). While it increases cardiac output in acute settings, long-term use of positive inotropes is actually associated with **increased mortality** due to arrhythmias and myocardial oxygen demand. * **Digoxin (Option C):** A cardiac glycoside that improves symptoms and reduces the rate of hospitalization (as shown in the DIG trial), but it has a **neutral effect on mortality**. **High-Yield Clinical Pearls for NEET-PG:** * **Mortality-Reducing Drugs in CHF:** ACE inhibitors (First line), ARBs (if ACEI intolerant), Beta-blockers (Bisoprolol, Carvedilol, Metoprolol succinate), Aldosterone antagonists (Spironolactone), and ARNI (Sacubitril/Valsartan). * **Digoxin Toxicity:** Characterized by gastrointestinal symptoms and xanthopsia (yellow vision). * **Beta-blockers:** Should only be started in **stable** CHF; they are contraindicated in acute decompensated heart failure.

Q: Sodium nitroprusside infusion may result in which of the following?

Cyanide toxicity. **Explanation:** **Sodium Nitroprusside (SNP)** is a potent, rapid-acting parenteral vasodilator used in hypertensive emergencies. Its mechanism involves the release of **Nitric Oxide (NO)**, which activates guanylyl cyclase, increasing cGMP and leading to the relaxation of both arteriolar and venous smooth muscles. **Why Cyanide Toxicity is the Correct Answer:** SNP is a complex molecule containing five cyanide groups. When infused, it reacts with hemoglobin to release **cyanide ions**. Normally, the liver enzyme **rhodanase** converts cyanide into the less toxic **thiocyanate**, which is then excreted by the kidneys. However, during prolonged or high-dose infusions, the body’s sulfur donors (thiosulfate) become exhausted, leading to cyanide accumulation. This inhibits mitochondrial cytochrome oxidase, causing cellular hypoxia and metabolic acidosis. **Analysis of Incorrect Options:** * **A. Hypertension:** SNP is a potent vasodilator used to *treat* severe hypertension; it causes rapid hypotension, not hypertension. * **B. Pulmonary Edema:** SNP reduces both preload and afterload, which actually helps in managing acute heart failure and pulmonary edema. * **D. Heart Block:** SNP does not typically affect the cardiac conduction system. Its primary cardiac side effect is reflex tachycardia due to rapid vasodilation. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote for Cyanide Toxicity:** Sodium thiosulfate (provides sulfur donors), Hydroxocobalamin (binds cyanide to form cyanocobalamin), or Nitrites (induce methemoglobinemia to sequester cyanide). * **Thiocyanate Toxicity:** Can occur in patients with renal failure, presenting with psychosis and seizures. * **Storage:** SNP is light-sensitive; the infusion bottle must be wrapped in opaque foil to prevent photodegradation. * **Monitoring:** Always monitor blood pressure continuously (via arterial line) and check acid-base status for signs of metabolic acidosis.

Q: Which of the following drugs predominantly acts by decreasing the preload of the heart?

Nitroglycerine. ### Explanation **1. Why Nitroglycerine is Correct:** Nitroglycerine (NTG) is a potent **venodilator**. At therapeutic doses, it acts primarily on the venous capacitance vessels. By dilating the veins, it increases venous pooling of blood, which reduces the volume of blood returning to the right atrium. This reduction in end-diastolic volume leads to a **decrease in preload**, thereby reducing myocardial oxygen demand. While it can dilate arteries at higher doses, its predominant clinical effect is on preload. **2. Why the Other Options are Incorrect:** * **Hydralazine & Minoxidil:** These are **pure arterial vasodilators**. They act directly on the smooth muscles of the arterioles, decreasing peripheral vascular resistance. Therefore, they primarily **decrease afterload**, not preload. * **Calcium Channel Blockers (CCBs):** Drugs like Nifedipine (Dihydropyridines) are potent **arteriolar dilators** (decreasing afterload). Verapamil and Diltiazem also have significant negative inotropic and chronotropic effects on the heart. They do not have a significant effect on venous capacitance (preload). **3. NEET-PG High-Yield Pearls:** * **Nitrates Mechanism:** They are prodrugs that release **Nitric Oxide (NO)**, which stimulates **guanylyl cyclase**, increasing **cGMP** and leading to dephosphorylation of myosin light chains (relaxation). * **Drug of Choice:** NTG is the drug of choice for acute anginal attacks (sublingual) and acute left ventricular failure (IV) because it "unloads" the heart. * **Tolerance:** Continuous use of nitrates leads to "tachyphylaxis" (tolerance) due to the depletion of free sulfhydryl (-SH) groups. A "nitrate-free interval" of 8–12 hours is required daily. * **Monday Disease:** Workers in dynamite factories exposed to nitrates develop tolerance during the week but lose it over the weekend, leading to headaches and tachycardia upon re-exposure on Mondays.

Q: Which antianginal drug can be safely used with drugs used for treatment of erectile dysfunction?

pFOX inhibitor. **Explanation:** The core clinical concern when combining antianginal drugs with erectile dysfunction (ED) medications (PDE-5 inhibitors like Sildenafil) is the risk of **severe, life-threatening hypotension**. **1. Why pFOX Inhibitors are correct:** pFOX (partial Fatty Acid Oxidation) inhibitors, primarily **Trimetazidine**, work by shifting the myocardial metabolism from fatty acid oxidation to glucose oxidation. This metabolic shift requires less oxygen to produce ATP, protecting the ischemic myocardium without affecting hemodynamics. Since pFOX inhibitors do not cause vasodilation or affect the Nitric Oxide (NO)-cGMP pathway, they do not interact with PDE-5 inhibitors and are safe to use concurrently. **2. Why the other options are incorrect:** * **Nitrates (Option D):** These are strictly contraindicated. Nitrates increase cGMP production, while PDE-5 inhibitors prevent cGMP breakdown. This synergistic effect leads to massive cGMP accumulation, causing profound systemic vasodilation and fatal hypotension. * **Potassium Channel Openers (Option C):** Drugs like **Nicorandil** have a dual mechanism; they open K+ channels and also possess a nitrate-like moiety. They can significantly potentiate the hypotensive effects of PDE-5 inhibitors. * **Calcium Channel Blockers (Option A):** While not strictly contraindicated like nitrates, CCBs (especially dihydropyridines) cause vasodilation. Combining them with PDE-5 inhibitors requires extreme caution due to the additive risk of hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **Ranolazine:** Another antianginal that inhibits the late sodium current ($I_{Na}$); it is also hemodynamically neutral and safe with ED drugs. * **Ivabradine:** A pure heart rate reducer (Funny current inhibitor) that is also safe to combine. * **Time Gap:** If a patient on Sildenafil requires nitrates, a minimum gap of **24 hours** is mandatory (48 hours for Tadalafil).

Q: Which of the following statements about digoxin is false?

Dosage reduction is required in hepatic disease.. **Explanation:** The correct answer is **A**, as digoxin is primarily eliminated by the kidneys, not the liver. **1. Why Option A is False (The Correct Answer):** Digoxin is a polar glycoside with a unique pharmacokinetic profile. Approximately **60-80% of the drug is excreted unchanged in the urine** via glomerular filtration and P-glycoprotein secretion. Since it does not undergo significant hepatic metabolism, its clearance is independent of liver function. Therefore, dosage reduction is **not** required in hepatic disease. **2. Why the other options are True:** * **Option B:** Because digoxin is primarily renally excreted, its half-life (normally 36–40 hours) increases significantly in **renal failure**, leading to toxicity. Dose adjustment based on creatinine clearance is mandatory. * **Option C:** Digoxin has **parasympathomimetic (vagotonic) effects**, which slow the conduction through the AV node and decrease the heart rate. This makes it useful in controlling ventricular rate in atrial fibrillation but can cause symptomatic bradycardia. * **Option D:** Digoxin is a **positive inotrope**. It inhibits the Na+/K+-ATPase pump, leading to an increase in intracellular sodium, which subsequently increases intracellular calcium via the Na+/Ca2+ exchanger. This enhances the force of myocardial contraction. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Digoxin Immune Fab (Digibind). * **Electrolyte Interactions:** **Hypokalemia**, hypomagnesemia, and hypercalcemia predispose to digoxin toxicity. * **ECG Changes:** The earliest sign of toxicity is often PVCs; the most characteristic sign is the "Reverse Tick" or "Sagging" ST-segment depression. * **Drug Interactions:** Quinidine, Verapamil, and Amiodarone increase digoxin levels by displacing it from tissue binding sites and reducing renal clearance.

Q: Nicotinic acid is useful in all types of hyperlipoproteinemias, EXCEPT:

Type-I. **Explanation:** Nicotinic acid (Niacin) is a broad-spectrum hypolipidemic agent that acts by inhibiting **hormone-sensitive lipase** in adipose tissue. This reduces the breakdown of triglycerides into free fatty acids (FFAs). Since FFAs are the primary substrate for hepatic VLDL synthesis, Niacin effectively lowers VLDL, and subsequently its metabolite, LDL. **Why Type-I is the Correct Answer:** * **Type-I Hyperlipoproteinemia (Familial Chylomicronemia)** is characterized by a deficiency in **Lipoprotein Lipase (LPL)** or its cofactor, ApoC-II. This leads to a massive accumulation of **Chylomicrons** in the plasma. * Niacin does not significantly affect the clearance of dietary chylomicrons; its primary mechanism is reducing endogenous VLDL production. Therefore, it is ineffective in treating Type-I. **Why the other options are incorrect:** * **Type-II (Familial Hypercholesterolemia):** Niacin reduces LDL levels by decreasing VLDL synthesis and inhibiting hepatic diacylglycerol acyltransferase-2. It is a potent agent for lowering LDL (Type-IIa) and VLDL (Type-IIb). * **Type-III (Dysbetalipoproteinemia):** Niacin helps reduce IDL (Remnant particles) by decreasing the precursor VLDL. * **Type-IV (Familial Hypertriglyceridemia):** Niacin is highly effective here as it directly inhibits VLDL secretion, which is the hallmark of Type-IV. **High-Yield Clinical Pearls for NEET-PG:** * **Most Potent Effect:** Niacin is the most effective drug for **increasing HDL levels** (by decreasing HDL catabolism). * **Lp(a) Reduction:** It is one of the few drugs that significantly lowers **Lipoprotein(a)**. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin $D_2$ and $E_2$), which can be prevented by taking **Aspirin** 30 minutes prior. * **Metabolic Risks:** It can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (acanthosis nigricans is a rare sign of insulin resistance here).

Question 1

Which of the following statements regarding verapamil is incorrect?

Accepted Answer

It is contraindicated in patients with supraventricular tachycardia.

Answer

It does not produce reflex tachycardia.

Answer

It is less potent as a coronary vasodilator.

Answer

It can cause constipation.

Question 2

A 40-year-old male patient has type II diabetes mellitus and hypertension. Which of the following antihypertensive drugs should be avoided in such patients?

Accepted Answer

Hydrochlorothiazide

Answer

Lisinopril

Answer

Losartan

Answer

Trandolopril

Question 3

Which among the following is the best inotrope drug for use in right heart failure?

Accepted Answer

Milrinone

Answer

Dobutamine

Answer

Digoxin

Answer

Dopamine

Question 4

Which of the following drugs can prolong survival in patients with Congestive Heart Failure (CHF)?

Accepted Answer

Losartan

Answer

Furosemide

Answer

Inamrinone

Answer

Digoxin

Question 5

ACE inhibitors are contraindicated in which of the following conditions?

Accepted Answer

Bilateral renal artery stenosis

Answer

Diabetes mellitus

Answer

Hypertension in old age groups

Answer

Scleroderma

Question 6

Sodium nitroprusside infusion may result in which of the following?

Accepted Answer

Cyanide toxicity

Answer

Hypertension

Answer

Pulmonary edema

Answer

Heart block

Question 7

Which of the following drugs predominantly acts by decreasing the preload of the heart?

Accepted Answer

Nitroglycerine

Answer

Calcium channel blockers

Answer

Minoxidil

Answer

Hydralazine

Question 8

Which antianginal drug can be safely used with drugs used for treatment of erectile dysfunction?

Accepted Answer

pFOX inhibitor

Answer

Calcium channel blockers

Answer

Potassium channel opener

Answer

Nitrates

Question 9

Which of the following statements about digoxin is false?

Accepted Answer

Dosage reduction is required in hepatic disease.

Answer

Dosage reduction is required in renal failure.

Answer

It can cause bradycardia.

Answer

It increases the force of contraction in congestive heart failure.

Question 10

Nicotinic acid is useful in all types of hyperlipoproteinemias, EXCEPT:

Accepted Answer

Type-I

Answer

Type-II

Answer

Type-III

Answer

Type-IV

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?